Commit Lozenge ads
TV spots for OTC smoking cessation lozenge airing now on major networks, GSK says. Designed by Arnold McGrath Worldwide, ads feature different angles of a lone cigarette against a simple background. "This thing you carry with you everywhere, this thing you obsess about and face ridicule for, this thing you're not sure you'll ever be able to quit, may have just met its match," a voiceover states, before detailing recommended use of Commit. TV spots will be complemented by 1Web site, newspaper ads in publications such as USA Today. Commit nicotine polacrilex lozenge debuted late last month, features "time to first cigarette" dosage selection tool (2"The Tan Sheet" Nov. 4, 2002, p. 3)...
More from Archive
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
While treatments for scleroderma are in development, none are approved for the condition that is associated with high morbidity and mortality. The European Medicines Agency says guidance on how to design development programs for the disorder is needed.
Madrigal Pharmaceuticals’ Rezdiffra is on track to become the first medicine approved in the EU for non-cirrhotic metabolic dysfunction-associated steatohepatitis after the European Medicines Agency recommended that it be granted conditional marketing authorization.
Highlights from Day Four of the BIO International Convention include policy concerns helping constrain dealmaking, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.